International Kidney Cancer Symposium | Conference

Research Aims to Make Inroads With CAR T-Cell Therapy in Advanced RCC

November 11th 2023

Although not immediately practice changing, CAR T-cell therapy has the potential to become a standard of care for patients with advanced renal cell carcinoma following progression on checkpoint inhibitors and VEGF inhibitors.

Deeper Understanding of Clonal Hematopoiesis Could Improve Cardiovascular Outcomes for Patients With Kidney Cancer

November 11th 2023

Additional research exploring the association between clonal hematopoiesis and cardiovascular health could help improve outcomes for patients with kidney cancer and identify those at higher risk for experiencing cardiac events.

Cancer Immunity Cycle Could Inform Development of Novel Immune Therapies in RCC

November 11th 2023

Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.

Treatment Decisions in RCC Could Be Aided by ctDNA

November 11th 2023

Decisions regarding the intensification or de-escalation of treatment, particularly with immunotherapy and TKIs, for patients with renal cell carcinoma could be aided by circulating tumor DNA.

Dr Ramnaraign on Retrospective Data For irAEs in Older Patients With Kidney Cancer

November 11th 2023

Brian H. Ramnaraign, MD, discusses findings from a single-institution review of the incidence of immunotherapy-related toxicities in older patients with kidney cancer.

Dr Tan on the Potential Utility of ctDNA in RCC

November 11th 2023

Alan Tan, MD, discusses the ongoing investigation and potential utility of circulating tumor DNA in patients with renal cell carcinoma.

LITESPARK-013 Data Support RP2D of Belzutifan as Standard Option in Advanced ccRCC

November 11th 2023

Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.

Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCC

November 11th 2023

Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.

Zanzalintinib Continues to Elicit Efficacy With Tolerability in Advanced ccRCC

November 10th 2023

Treatment with zanzalintinib monotherapy produced antitumor activity and was well tolerated in patients with previously treated advanced clear cell renal cell carcinoma.

Considering the Data Behind Belzutifan's Approval in VHL Disease–Associated Cancers

November 10th 2023

Jaleh Fallah, MD, discusses the FDA's evaluation of data from the phase 2 LITESPARK-004 trial, which supported the approval of belzutifan in von Hippel-Lindau–associated cancers.

Dr Pal on Outcomes With the Use of Zanzalintinib in Relapsed/Refractory ccRCC

November 10th 2023

Sumanta Kumar Pal, MD, FASCO, discusses outcomes with the use of zanzalintinib in patients with relapsed/refractory clear cell renal cell carcinoma.

Treatments for Translocation RCC Require Novel Therapeutic Targets

November 10th 2023

Immune checkpoint inhibitors have been associated with improved outcomes for patients with metastatic translocation renal cell carcinoma; however, novel therapies and therapeutic targets are needed for patients within this histologic subset.

Emerging Therapies Prompt Nuanced AE Management in Kidney Cancer

November 6th 2022

Kiran Virdee, RN, BSN, CCRN-K, outlines the best practices for the management of adverse effects during the treatment of kidney cancer.

Investigators Debate Frontline Doublet Vs Triplet Therapy in RCC

November 5th 2022

Rana M. McKay, MD, and Yousef Zakharia, MD, debate the pros and cons of doublet vs triplet combination therapies in the frontline setting for patients with renal cell carcinoma.

Tivozanib Maintains Long-Term PFS Benefit Over Sorafenib in Relapsed/Refractory RCC

November 5th 2022

Tivozanib continued to display a progression-free survival benefit and rates vs sorafenib in patients with relapsed/refractory renal cell carcinoma who received 2 or 3 prior systemic regimens.

Dr. McKay on Tivozanib Plus Nivolumab in Advanced RCC

November 4th 2022

Rana R. McKay, MD, discusses the rationale for combining tivozanib with nivolumab in heavily pretreated patients with renal cell carcinoma.

Nivolumab/Ipilimumab Improves Survival in Untreated, Advanced Sarcomatoid RCC

November 4th 2022

The combination of nivolumab and ipilimumab led to significant improvements in survival vs sunitinib in patients with intermediate- and poor-risk renal cell carcinoma with sarcomatoid features.

Lenvatinib/Pembrolizumab Reduces Need for Subsequent Therapy in Advanced RCC

November 4th 2022

Lenvatinib plus pembrolizumab reduced the need for second-line therapy by 42.8% compared with sunitinib in patients with advanced renal cell carcinoma.

Dr. McGregor on Belzutifan Plus Lenvatinib in Advanced RCC

November 4th 2022

Bradley McGregor, MD, discusses the rationale behind combining belzutifan with lenvatinib in pretreated patients with advanced renal cell carcinoma with clear cell components.

Dr. Jonasch on the Exploration of Cabozantinib in the Neoadjuvant Setting in RCC

November 4th 2022

Eric Jonasch, MD, discusses the exploration of cabozantinib in the neoadjuvant setting in renal cell carcinoma.